Pharmaceutical companies claim victory, but are far from satisfied
- Pharmaceutical and biotech companies are fiercely opposing a European plan to curtail ownership rights on new medicines.
- Successfully: the European Commission has now opted to maintain a protection period of eight years.
- The sector hopes that Europe, partly under pressure from President Trump, will pay higher prices for new medicines.
The pharmaceutical industry lobbied for two years against a European legislative proposal that threatened to cost drug manufacturers a lot of money. It was taken off the table last month, but the sector wants more. 'I look at the defense companies with some envy.'
fd.nl
%2Fs3%2Fstatic.nrc.nl%2Fwp-content%2Fuploads%2F2025%2F07%2F06072253%2FUS-DEATH-TOLL-RISES-AFTER-FLASH-FLOODS-IN-HILL-COUNTRY-TEXAS_68885289.jpg&w=3840&q=100)
%2Fs3%2Fstatic.nrc.nl%2Fwp-content%2Fuploads%2F2025%2F07%2F05212219%2FAFP_64VZ7BG.jpg&w=3840&q=100)